Linked Life Data

20818444

Source:http://linkedlifedata.com/resource/pubmed/id/20818444

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2011-6-9
pubmed:abstractText
Rasburicase was administered at a fixed dose of 3?mg to treat 287 episodes of elevated serum uric acid levels (>7?mg/dL) in 247 adult patients with hematological malignancies. The median total dose of 36??g/kg (range: 18-65) was a fraction of the recommended total pediatric dose of 0.75-1.0?mg/kg. The median change in uric acid levels at 24?h was -4.1?mg/dL (range: -12 to +1) and -45% (range: -95 to +9). Uric acid levels normalized at 24?h in 72% of patients. There was no relationship between the weight-based dose and uric acid decline. The only predictor of success was the baseline uric acid; the failure rate was 84% with baseline level >12?mg/dL and 18% if it was ? 12. Uric acid levels continued to decline beyond 24?h in most patients without additional treatment. Serum creatinine remained stable over 24?h, and declined over 48?h and 7 days. There was no relationship between the extent of reduction in uric acid levels and serum creatinine. We conclude that a single 3-mg dose of rasburicase, used with close monitoring, is sufficient to treat most adults with uric acid levels up to 12?mg/dL.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1476-5365
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
800-5
pubmed:meshHeading
pubmed:year
2011
pubmed:articleTitle
Effectiveness of a single 3-mg rasburicase dose for the management of hyperuricemia in patients with hematological malignancies.
pubmed:affiliation
Northwestern Memorial Hospital, and The Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
pubmed:publicationType
Journal Article